iBio, Inc. (IBIO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.36 M

Shareholding (Mar 2025)

FII

9.34%

Held by 7 FIIs

DII

87.97%

Held by 3 DIIs

Promoter

0.00%

How big is iBio, Inc.?

22-Jun-2025

As of Jun 18, iBio, Inc. has a market capitalization of 13.22 million, classifying it as a Micro Cap company, with net sales of 0.37 million and a net profit of -16.46 million over the latest four quarters. As of Jun 24, the company's shareholder's funds were 21.32 million, and total assets were 28.73 million.

What does iBio, Inc. do?

22-Jun-2025

iBio, Inc. is a biotechnology company focused on commercializing technologies and product candidates in the Pharmaceuticals & Biotechnology industry, with a market cap of $13.22 million and a recent net profit of -$5 million. The company has no dividend yield and operates at a loss, reflected in its negative financial metrics.

Who are in the management team of iBio, Inc.?

22-Jun-2025

As of March 2022, the management team of iBio, Inc. includes Chairman and CEO Thomas Isett, Interim Secretary and Treasurer Robert Kay, and independent directors Linda Armstrong, Glenn Chang, Seymour Flug, Gen. (Retd.) James Hill, and Alexandra Kropotova. They are responsible for the company's governance and strategic direction.

Is iBio, Inc. overvalued or undervalued?

25-Jun-2025

As of October 15, 2023, iBio, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.3, indicating a solid financial position compared to peers like Moderna and Novavax.

Is iBio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, iBio, Inc. is in a mildly bearish trend, with daily moving averages and weekly Dow Theory indicating weakness, despite some mildly bullish signals from MACD and KST, and it has underperformed the S&P 500 with a year-to-date return of -64.49%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 17 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.49

Return on Equity

-123.50%

Price to Book

1.13

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

57.77%

6 Months

29.52%

1 Year

-51.52%

2 Years

-52.59%

3 Years

-96.24%

4 Years

-99.61%

5 Years

-14.09%

iBio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is iBio, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for iBio, Inc. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a mildly bearish trend and the weekly Dow Theory showing a bearish signal. While the MACD and KST are mildly bullish on a weekly basis, the overall indicators suggest weakness. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -64.49% versus the S&P 500's 12.22%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-24.59%

EBIT Growth (5y)

-7.66%

EBIT to Interest (avg)

-21.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

35.01%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.43

EV to EBIT

-0.76

EV to EBITDA

-0.82

EV to Capital Employed

1.61

EV to Sales

12.85

PEG Ratio

Dividend Yield

ROCE (Latest)

-211.17%

ROE (Latest)

-144.63%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (2.69%)

Foreign Institutions

Held by 7 Foreign Institutions (9.34%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -6.12% vs -11.36% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.90",
          "val2": "-4.60",
          "chgp": "-6.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-4.90",
          "chgp": "-6.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-25,990.00%",
          "val2": "0.00%",
          "chgp": "-2,599.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 47.44% vs 0.68% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.40",
          "val2": "-27.70",
          "chgp": "44.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.40",
          "val2": "-29.30",
          "chgp": "47.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-73,928.90%",
          "val2": "0.00%",
          "chgp": "-7,392.89%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-4.90

-4.60

-6.52%

Interest

0.00

0.10

-100.00%

Exceptional Items

0.00

Consolidate Net Profit

-5.20

-4.90

-6.12%

Operating Profit Margin (Excl OI)

-25,990.00%

0.00%

-2,599.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -6.12% vs -11.36% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'24

Jun'24

Jun'23

Change(%)

Net Sales

0.20

0.00

Operating Profit (PBDIT) excl Other Income

-15.40

-27.70

44.40%

Interest

0.20

0.10

100.00%

Exceptional Items

0.00

-0.60

100.00%

Consolidate Net Profit

-15.40

-29.30

47.44%

Operating Profit Margin (Excl OI)

-73,928.90%

0.00%

-7,392.89%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs -100.00% in Jun 2023

Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 47.44% vs 0.68% in Jun 2023

All Annual Results

Company CV

About iBio, Inc.

iBio, Inc.

Pharmaceuticals & Biotechnology

iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.

Company Coordinates

Company Details

600 Madison Ave Ste 1601 , NEW YORK NY : 10022-1737

Tel: 1 302 35506501 646 2743580

https://www.ibioinc.com/

Registrar Details

iBio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is iBio, Inc.?

Watch in Real-Time

What does iBio, Inc. do?

Who are in the management team of iBio, Inc.?

Is iBio, Inc. overvalued or undervalued?

Is iBio, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is iBio, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Jun'24

About iBio, Inc.

Company Coordinates